COLUMBIA, SC--(MARKET WIRE)--Feb 2, 2009 -- Blood Diagnostics, Inc., a national leader in the distribution of biopharmaceutical products, announced that effective February 1, 2009 the company will begin operations from its new corporate headquarters under the corporation’s new name -- BDI Pharma, Inc. The company will remain independent with the same ownership as it has for the past 14 years.
Despite the economic downturn, BDI Pharma, Inc. achieved significant growth in excess of 21 percent and 28 percent in 2007 and 2008, respectively. The company has reported double-digit growth in sales revenue in each of the last six fiscal years due to expanded product offerings and robust client development. “The transition to a new corporate headquarters and our new name reflects the substantial, but closely and conservatively managed, growth of our organization,” said Eddie Stiefel, Jr., co-president of BDI Pharma, Inc. “We will now serve our customers with even greater resources and enhanced services capabilities.”
The new state-of-the-art corporate headquarters, located in Columbia, SC, serves as the primary distribution center and provides more than threefold the office space and warehousing capabilities of the company’s previous facility. This new space will accommodate the continued expansion of personnel, which grew by 20 percent over the last twelve months, and product line offerings. “We are committed to servicing the growing needs of our healthcare providers and manufacturing trade partners while maintaining our niche market roots,” said Co-President Richard J. Gaton. “BDI Pharma remains dedicated to providing the same level of service and expertise in the distribution of additional specialty pharmaceuticals.”
For more information about BDI Pharma, refer to www.bdipharma.com or 800.948.9834
About BDI Pharma, Inc.
Serving the healthcare community since 1995, BDI Pharma, Inc., the preeminent national wholesaler of specialty biopharmaceutical products, has built an outstanding reputation as an industry source for products and service. BDI Pharma, Inc.'s market focus is evident in its commitment to specialty biotherapeutics, immunologics and hemostatics, including Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, as well as hyper-immunes, injectables and physician specialty pharmaceuticals. As a recognized Authorized Distributor of Record for the products it supplies from distribution centers located on both the East and West coast, BDI Pharma, Inc. services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.
In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma, Inc. defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma, Inc.'s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace. Contact:
Contact: Brad Davis Director of Marketing Email Contact (800) 948-9834